AnaptysBio, Inc. (NASDAQ: ANAB) reported Q2 EPS of ($1.71), $0.67 worse than the analyst estimate of ($1.04). Revenue for the quarter came in at $10.97 million versus the consensus estimate of $22.76 million.

For earnings history and earnings-related data on AnaptysBio, Inc. (ANAB) click here.